表紙
市場調査レポート

尋常性座瘡 : パイプライン分析

Acne Vulgaris - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232807
出版日 ページ情報 英文 182 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
尋常性座瘡 : パイプライン分析 Acne Vulgaris - Pipeline Review, H1 2016
出版日: 2016年04月27日 ページ情報: 英文 182 Pages
概要

尋常性座瘡とは、顔および上躯幹の毛包脂腺小胞の異常であり、吹き出ものが炎症を起こし、膿疱、結節、嚢胞などになると、痛みを持つ場合もあります。青年期、ヘアジェル、油性の化粧品、ヘルメットのストラップの摩擦などスポーツ用品、皮膚の閉塞などが素因となり、抗生物質で治療します。

当レポートでは、世界における尋常性座瘡治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

尋常性座瘡の概要

治療薬の開発

  • 尋常性座瘡向けパイプライン製品:概要
  • 尋常性座瘡向けパイプライン製品:比較分析

尋常性座瘡:開発中の治療薬:企業別

尋常性座瘡:開発中の治療薬:大学・研究機関別

尋常性座瘡:パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

尋常性座瘡:開発中の製品:企業別

尋常性座瘡:開発中の製品:大学・研究機関別

尋常性座瘡:治療薬開発に従事している企業

  • 3SBio Inc.
  • Advancell
  • Allergan Plc
  • Almirall, S.A.
  • Biomar Microbial Technologies
  • Braintree Laboratories, Inc.
  • Brickell Biotech, Inc.
  • Celtaxsys, Inc.
  • Cosmo Pharmaceuticals S.p.A
  • Delenex Therapeutics AG
  • Deltanoid Pharmaceuticals Inc.
  • DermaXon, LLC
  • Dermira Inc.
  • ELORAC, Inc.
  • Ensol Biosciences Inc.
  • Foamix Pharmaceuticals Ltd.
  • Galderma S.A.
  • GlaxoSmithKline Plc
  • Helix BioMedix, Inc.
  • Hovione FarmaCiencia SA
  • Lee's Pharmaceutical Holdings Limited
  • マルホ
  • Novabiotics Limited
  • Novan, Inc.
  • OrigImm e.U.
  • Paratek Pharmaceuticals, Inc.
  • Phosphagenics Limited
  • Photocure ASA
  • Promius Pharma, LLC
  • Provectus Biopharmaceuticals, Inc.
  • RestorGenex Corporation
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • SkyePharma Plc
  • Telesso Technologies Limited
  • Thesan Pharmaceuticals, Inc.
  • 富山化学工業
  • Valeant Pharmaceuticals International, Inc.
  • Venn Life Sciences Holdings Plc
  • Vyome Biosciences Private Limited
  • Xenon Pharmaceuticals Inc.

尋常性座瘡:治療薬の評価

  • 単剤治療薬
  • コンビネーション製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (アダパレン + 過酸化ベンゾイル)
  • (アダパレン + 塩酸クリンダマイシン)
  • (リン酸クリンダマイシン + トレチノイン)
  • acebilustat
  • Aczone X
  • AD-037
  • アミノレブリン酸塩酸塩
  • ANs-29
  • AQ-401
  • B-244
  • BBI-3000
  • becocalcidiol
  • 過酸化ベンゾイル
  • 過酸化ベンゾイル
  • BLI-1100
  • CB-0301
  • CB-0604
  • DFD-10
  • DLX-2323
  • DLX-2681
  • DRM-01
  • 座瘡薬
  • DX-0385
  • E-10215
  • finasteride
  • FMX-101
  • GSK-1940029
  • HB-1345
  • Hesed-4000
  • IB-07A037
  • IDP-120
  • IDP-121
  • IDP-123
  • methyl aminolevulinate hydrochloride
  • ミノサイクリン
  • ミノサイクリン
  • MTC-896
  • NAI-003
  • NVN-1000
  • omiganan pentahydrochloride
  • onabotulinumtoxin A
  • ozenoxacin
  • 座瘡・皮膚癌向け細菌細胞膜・細胞壁破壊ペプチド
  • PH-10
  • RES-440
  • sarecycline hydrochloride
  • SKP-026
  • 座瘡・皮膚炎向け小分子
  • SYN-1113
  • 尋常性座瘡向け合成ペプチド
  • 免疫学、皮膚疾患、遺伝性疾患向けカリクレイン阻害合成ペプチド
  • トレチノイン
  • trifarotene
  • 座瘡ワクチン
  • 座瘡ワクチン
  • VB-1953
  • XEN-801
    • 製品概要
    • 作用機序
    • R&Dの進捗

最新のパイプライン動向

休止中のプロジェクト

開発中止の製品

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7823IDB

Summary

Global Markets Direct's, 'Acne Vulgaris - Pipeline Review, H1 2016', provides an overview of the Acne Vulgaris pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acne Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acne Vulgaris
  • The report reviews pipeline therapeutics for Acne Vulgaris by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Acne Vulgaris therapeutics and enlists all their major and minor projects
  • The report assesses Acne Vulgaris therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Acne Vulgaris

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acne Vulgaris Overview
  • Therapeutics Development
    • Pipeline Products for Acne Vulgaris - Overview
    • Pipeline Products for Acne Vulgaris - Comparative Analysis
  • Acne Vulgaris - Therapeutics under Development by Companies
  • Acne Vulgaris - Therapeutics under Investigation by Universities/Institutes
  • Acne Vulgaris - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Acne Vulgaris - Products under Development by Companies
  • Acne Vulgaris - Products under Investigation by Universities/Institutes
  • Acne Vulgaris - Companies Involved in Therapeutics Development
    • 3SBio Inc.
    • Ache Laboratorios Farmaceuticos S/A
    • Allergan Plc
    • Almirall, S.A.
    • Biomar Microbial Technologies
    • Braintree Laboratories, Inc.
    • Brickell Biotech, Inc.
    • Celtaxsys, Inc.
    • Delenex Therapeutics AG
    • DermaXon, LLC
    • Dermira Inc.
    • Diffusion Pharmaceuticals Inc.
    • ELORAC, Inc.
    • Ensol Biosciences Inc.
    • Foamix Pharmaceuticals Ltd.
    • Galderma S.A.
    • GlaxoSmithKline Plc
    • Helix BioMedix, Inc.
    • Hovione FarmaCiencia SA
    • Lee's Pharmaceutical Holdings Limited
    • Novabiotics Limited
    • Novan, Inc.
    • Paratek Pharmaceuticals, Inc.
    • Phosphagenics Limited
    • Photocure ASA
    • Promius Pharma, LLC
    • Provectus Biopharmaceuticals, Inc.
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
    • SkyePharma Plc
    • Sol-Gel Technologies Ltd.
    • Telesso Technologies Limited
    • Thesan Pharmaceuticals, Inc.
    • Valeant Pharmaceuticals International, Inc.
    • Venn Life Sciences Holdings Plc
    • Vyome Biosciences Private Limited
    • XBiotech USA, Inc.
    • Xenon Pharmaceuticals Inc.
  • Acne Vulgaris - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (adapalene + benzoyl peroxide) - Drug Profile
    • (adapalene + benzoyl peroxide) - Drug Profile
    • (adapalene + clindamycin hydrochloride) - Drug Profile
    • (benzoyl peroxide + tretinoin) - Drug Profile
    • (clindamycin phosphate + tretinoin) - Drug Profile
    • A-3APO - Drug Profile
    • acebilustat - Drug Profile
    • Aczone X - Drug Profile
    • AD-037 - Drug Profile
    • aminolevulinic acid hydrochloride - Drug Profile
    • ANT-1207 - Drug Profile
    • AQ-401 - Drug Profile
    • ATx-202 - Drug Profile
    • B-244 - Drug Profile
    • BBI-3000 - Drug Profile
    • benzoyl peroxide - Drug Profile
    • BLI-1100 - Drug Profile
    • CB-0301 - Drug Profile
    • DFD-10 - Drug Profile
    • DLX-2323 - Drug Profile
    • DLX-2681 - Drug Profile
    • DMT-210 - Drug Profile
    • DRM-01 - Drug Profile
    • Drugs for Acne - Drug Profile
    • DX-0385 - Drug Profile
    • DX-0386 - Drug Profile
    • E-10215 - Drug Profile
    • finasteride - Drug Profile
    • FMX-101 - Drug Profile
    • GSK-1940029 - Drug Profile
    • HB-1345 - Drug Profile
    • Hesed-4000 - Drug Profile
    • IB-07A037 - Drug Profile
    • IDP-120 - Drug Profile
    • IDP-121 - Drug Profile
    • IDP-123 - Drug Profile
    • IDP-126 - Drug Profile
    • IDP-129 - Drug Profile
    • IDP-130 - Drug Profile
    • methyl aminolevulinate hydrochloride - Drug Profile
    • minocycline - Drug Profile
    • minocycline - Drug Profile
    • MTC-896 - Drug Profile
    • NAI-003 - Drug Profile
    • omiganan pentahydrochloride - Drug Profile
    • Peptide to Disrupt Bacterial Cell Membrane and Cell Wall for Acne And Skin Cancer - Drug Profile
    • PH-10 - Drug Profile
    • RA-18C3 - Drug Profile
    • RES-440 - Drug Profile
    • sarecycline hydrochloride - Drug Profile
    • SB-204 - Drug Profile
    • SKP-026 - Drug Profile
    • Small Molecule for Acne and Skin Inflammation - Drug Profile
    • SYN-1113 - Drug Profile
    • Synthetic Peptide for Acne Vulgaris - Drug Profile
    • Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile
    • tretinoin - Drug Profile
    • trifarotene - Drug Profile
    • Vaccine for Acne Vulgaris - Drug Profile
    • VB-1953 - Drug Profile
    • XEN-801 - Drug Profile
  • Acne Vulgaris - Recent Pipeline Updates
  • Acne Vulgaris - Dormant Projects
  • Acne Vulgaris - Discontinued Products
  • Acne Vulgaris - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acne Vulgaris, H1 2016
  • Number of Products under Development for Acne Vulgaris - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Acne Vulgaris - Pipeline by 3SBio Inc., H1 2016
  • Acne Vulgaris - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016
  • Acne Vulgaris - Pipeline by Allergan Plc, H1 2016
  • Acne Vulgaris - Pipeline by Almirall, S.A., H1 2016
  • Acne Vulgaris - Pipeline by Biomar Microbial Technologies, H1 2016
  • Acne Vulgaris - Pipeline by Braintree Laboratories, Inc., H1 2016
  • Acne Vulgaris - Pipeline by Brickell Biotech, Inc., H1 2016
  • Acne Vulgaris - Pipeline by Celtaxsys, Inc., H1 2016
  • Acne Vulgaris - Pipeline by Delenex Therapeutics AG, H1 2016
  • Acne Vulgaris - Pipeline by DermaXon, LLC, H1 2016
  • Acne Vulgaris - Pipeline by Dermira Inc., H1 2016
  • Acne Vulgaris - Pipeline by Diffusion Pharmaceuticals Inc., H1 2016
  • Acne Vulgaris - Pipeline by ELORAC, Inc., H1 2016
  • Acne Vulgaris - Pipeline by Ensol Biosciences Inc., H1 2016
  • Acne Vulgaris - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016
  • Acne Vulgaris - Pipeline by Galderma S.A., H1 2016
  • Acne Vulgaris - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Acne Vulgaris - Pipeline by Helix BioMedix, Inc., H1 2016
  • Acne Vulgaris - Pipeline by Hovione FarmaCiencia SA, H1 2016
  • Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016
  • Acne Vulgaris - Pipeline by Novabiotics Limited, H1 2016
  • Acne Vulgaris - Pipeline by Novan, Inc., H1 2016
  • Acne Vulgaris - Pipeline by Paratek Pharmaceuticals, Inc., H1 2016
  • Acne Vulgaris - Pipeline by Phosphagenics Limited, H1 2016
  • Acne Vulgaris - Pipeline by Photocure ASA, H1 2016
  • Acne Vulgaris - Pipeline by Promius Pharma, LLC, H1 2016
  • Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016
  • Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2016
  • Acne Vulgaris - Pipeline by SkyePharma Plc, H1 2016
  • Acne Vulgaris - Pipeline by Sol-Gel Technologies Ltd., H1 2016
  • Acne Vulgaris - Pipeline by Telesso Technologies Limited, H1 2016
  • Acne Vulgaris - Pipeline by Thesan Pharmaceuticals, Inc., H1 2016
  • Acne Vulgaris - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016
  • Acne Vulgaris - Pipeline by Venn Life Sciences Holdings Plc, H1 2016
  • Acne Vulgaris - Pipeline by Vyome Biosciences Private Limited, H1 2016
  • Acne Vulgaris - Pipeline by XBiotech USA, Inc., H1 2016
  • Acne Vulgaris - Pipeline by Xenon Pharmaceuticals Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Acne Vulgaris Therapeutics - Recent Pipeline Updates, H1 2016
  • Acne Vulgaris - Dormant Projects, H1 2016
  • Acne Vulgaris - Dormant Projects (Contd..1), H1 2016
  • Acne Vulgaris - Dormant Projects (Contd..2), H1 2016
  • Acne Vulgaris - Dormant Projects (Contd..3), H1 2016
  • Acne Vulgaris - Dormant Projects (Contd..4), H1 2016
  • Acne Vulgaris - Dormant Projects (Contd..5), H1 2016
  • Acne Vulgaris - Dormant Projects (Contd..6), H1 2016
  • Acne Vulgaris - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Acne Vulgaris, H1 2016
  • Number of Products under Development for Acne Vulgaris - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top